Literature DB >> 10585576

Role of MT-MMPs and MMP-2 in pancreatic cancer progression.

V Ellenrieder1, B Alber, U Lacher, S F Hendler, A Menke, W Boeck, M Wagner, M Wilda, H Friess, M Büchler, G Adler, T M Gress.   

Abstract

Activation of matrix metalloproteinase-2 (MMP-2) by the membrane-type matrix metalloproteinases (MT-MMPs) has been associated with tumor progression. In the present study, we examined the role of MMP-2 and its activators MT1-MMP, MT2-MMP and MT3-MMP in pancreatic tumor cell invasion and the development of the desmoplastic reaction characteristic of pancreatic cancer tissues. Northern blot analyses revealed that transcript levels of MT1-MMP and MT2-MMP, but not MT3-MMP, were enhanced in pancreatic cancer tissues (n = 18) compared with both chronic pancreatitis (n = 9) and healthy pancreas (n = 9). A good correlation was found between MT1-MMP and both MMP-2 expression (p < 0.01) and activity in pancreatic cancer tissues. In addition, expression and activation of MMP-2 were strongly associated with the extent of the desmoplastic reaction in pancreatic cancer tissues. Invasion assays showed a good correlation between MMP-2 expression and activity and the invasive potential of pancreatic cancer cell lines. In cell lines with high levels of MMP-2 expression and activity, the MMP inhibitor Batimastat led to significant reduction of the number of invading cells. Our results suggest that MT1-MMP is involved in the progression of pancreatic cancer via activation of MMP-2. MMP-2 itself plays an important role in tumor cell invasion and appears to be associated with the development of the characteristic desmoplastic reaction in pancreatic cancer. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10585576     DOI: 10.1002/(sici)1097-0215(20000101)85:1<14::aid-ijc3>3.0.co;2-o

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  59 in total

1.  (18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts.

Authors:  Nemil Shah; Guihua Zhai; Joseph A Knowles; Cecil R Stockard; William E Grizzle; Naomi Fineberg; Tong Zhou; Kurt R Zinn; Eben L Rosenthal; Hyunki Kim
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

2.  Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy.

Authors:  Hyunki Kim; Guihua Zhai; Zhiyong Liu; Sharon Samuel; Nemil Shah; Emily E Helman; Joseph A Knowles; Cecil R Stockard; Naomi S Fineberg; William E Grizzle; Tong Zhou; Kurt R Zinn; Eben L Rosenthal
Journal:  Anticancer Drugs       Date:  2011-10       Impact factor: 2.248

Review 3.  Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment.

Authors:  Xuqi Li; Qingyong Ma; Qinhong Xu; Wanxing Duan; Jianjun Lei; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Proteolytic action of kallikrein-related peptidase 7 produces unique active matrix metalloproteinase-9 lacking the C-terminal hemopexin domains.

Authors:  Vishnu C Ramani; Gur P Kaushal; Randy S Haun
Journal:  Biochim Biophys Acta       Date:  2011-05-17

5.  Osteonectin influences growth and invasion of pancreatic cancer cells.

Authors:  Ahmed Guweidhi; Jörg Kleeff; Hassan Adwan; Nathalia A Giese; Moritz N Wente; Thomas Giese; Markus W Büchler; Martin R Berger; Helmut Friess
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

Review 6.  Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.

Authors:  Ibrahim H Sahin; Christine A Iacobuzio-Donahue; Eileen M O'Reilly
Journal:  Expert Opin Ther Targets       Date:  2015-10-06       Impact factor: 6.902

7.  Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.

Authors:  Hyunki Kim; Guihua Zhai; Sharon L Samuel; Christopher J Rigell; Heidi R Umphrey; Samir Rana; Cecil R Stockard; Naomi S Fineberg; Kurt R Zinn
Journal:  Mol Cancer Ther       Date:  2011-12-27       Impact factor: 6.261

Review 8.  Pancreatic stellate cells--role in pancreas cancer.

Authors:  Max G Bachem; Shaoxia Zhou; Karin Buck; Wilhelm Schneiderhan; Marco Siech
Journal:  Langenbecks Arch Surg       Date:  2008-01-17       Impact factor: 3.445

9.  Suppression of pancreatic cancer cell invasion by a cyclooxygenase-2-specific inhibitor.

Authors:  Jiro Okami; Shoji Nakamori; Nobuaki Hiraoka; Masanori Tsujie; Nobuyasu Hayashi; Hirofumi Yamamoto; Yoshiyuki Fujiwara; Hiroaki Nagano; Keizo Dono; Koji Umeshita; Masato Sakon; Morito Monden
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

10.  New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies.

Authors:  Laetitia Devy; Daniel T Dransfield
Journal:  Biochem Res Int       Date:  2010-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.